Combined Pioglitazone and Sulfonylurea Increase Serum Adiponectin and Lower Serum Macrophage Chemoattractant Protein-1 Concentrations in Patients with Type 2 Diabetes Mellitus
|
Accession number;05A0269251
|
| Title;Combined Pioglitazone and Sulfonylurea Increase Serum Adiponectin and Lower Serum Macrophage Chemoattractant Protein-1 Concentrations in Patients with Type 2 Diabetes Mellitus |
| Author;
MINE SHIN'ICHIRO
(Nakamashibyoin Naika)
OKADA YOSUKE
(Univ. Occupational and Environmental Health, School of Medicine, Dep. Surgery 2, JPN)
TAKAGI ICHIRO
(Nakamashibyoin Naika)
TANAKA AYA
(Nakamashibyoin Naika)
MORI HIROKO
(Nakamashibyoin Naika)
URIU KOHEI
(Nakamashibyoin Naika)
KAWAHARA CHIE
(Univ. Occupational and Environmental Health, School of Medicine, Dep. Surgery 2, JPN)
MORITA EMIKO
(Univ. Occupational and Environmental Health, School of Medicine, Dep. Surgery 2, JPN)
TANAKA YOSHIYA
(Univ. Occupational and Environmental Health, School of Medicine, Dep. Surgery 2, JPN)
|
Journal Title;Journal of the Japan Diabetic Society
|
Journal Code:Z0279B
|
ISSN:0021-437X
|
|
VOL.48;NO.2;PAGE.89-95(2005)
|
| Figure&Table&Reference;FIG.5, TBL.1, REF.18 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Previous studies have indicated that adiponectin alters insulin sensitivity and is involved in atherosclerosis in patients with diabetes mellitus (DM). We studied the influence of orally administered pioglitazone on the concentration of serum adiponectin and macrophage chemoattractant protein (MCP)-1 concentrations in patients with type 2 DM. Subjects were 26 healthy individuals and 109 diabetic patients (diet therapy 44; sulfonylurea (SU) 42; SU + pioglitazone 18; SU + metfolmine 5). We found that (1) serum adiponectin was significantly higher (p<0.01) in the SU + pioglitazone group than in the SU or SU + metfolmine group; (2) serum MCP-1 was significantly lower (p<0.05) in the SU + pioglitazone group than in other groups; (3) high serum adiponectin and low serum MCP-1 in patients on pioglitazone were detected within 12 months of administration; and (4) serum MCP-1 correlated significantly and negatively with serum adiponectin. The fact that pioglitazone combination therapy reduced MCP-1 concentrations and increased adiponectin concentrations suggests it has a more favorable therapeutic effect on patients with DM, including possible prevention of atherosclerosis, through the control of blood glucose and improvement of vascular disorders. (author abst.) |
|
|
|
Related Articles;
|
|
|
